Agalsidase Beta and Weed
Edited by Hugh Soames
Advertising: We may earn a commission if you buy anything via our advertising or external links
Agalsidase Beta and Weed
Most people who consume marijuana do so for its mood-altering and relaxing abilities. Weed gives people a high and allows them to relax. However, heavy consumption of weed can cause unwanted results. It can increase the anxiety and depression a person experiences, and it can interact with certain other drugs including Agalsidase Beta. It is important to remember that interactions do occur with all types of drugs, to a great or lesser extent and this article details the interactions of mixing Agalsidase Beta and Weed.
Mixing Agalsidase Beta and Weed
α-Galactosidase ( EC 3.2.1.22, α-GAL, α-GAL A; systematic name α-D-galactoside galactohydrolase) is a glycoside hydrolase enzyme that catalyses the following reaction:
It catalyzes many catabolic processes, including cleavage of glycoproteins, glycolipids, and polysaccharides.
The enzyme is encoded by the GLA gene. Two recombinant forms of human α-galactosidase are called agalsidase α (INN) and agalsidase β (INN). A mold-derived form is the primary ingredient in gas relief supplements.
This enzyme is a homodimeric glycoprotein that hydrolyses the terminal α-galactosyl moieties from glycolipids and glycoproteins. It predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose.
Defects in human α-GAL result in Fabry disease, a rare lysosomal storage disorder and sphingolipidosis that results from a failure to catabolize α-D-galactosyl glycolipid moieties. Characteristic features include episodes of pain in hands and feet (acroparesthesia), dark red spots on skin (angiokeratoma), decreased sweating (hypohidrosis), decreased vision (corneal opacity), gastrointestinal problems, hearing loss, tinnitus, etc.. Complications may be life-threatening and may include progressive kidney damage, heart attack, and stroke. This disease may have late onset and only affect the heart or kidneys.
Fabry disease is an X-linked disease, affecting 1 in 40,000 males. However, unlike other X-linked diseases, this condition also creates significant medical problems for females carrying only 1 copy of the defective GLA gene. These women may experience many classic symptoms of the disorder including cardiac and kidney problems. However, a small number of females carrying only one copy of the mutated GLA gene never shows any symptoms of Fabry disease.
Mutations to the GLA gene encoding α-GAL may result in complete loss of function of the enzyme. α-GAL is a lysosomal protein responsible for breaking down globotriaosylceramide, a fatty substance stored various types of cardiac and renal cells. When globotriaosylceramide is not properly catabolized, it is accumulated in cells lining blood vessels in the skin, cells in the kidney, heart and nervous system. As a result, signs and symptoms of Fabry disease begin to manifest.
There are three treatment options for Fabry disease: recombinant enzyme replacement therapy, pharmacological chaperone therapy, and organ specific treatment.
RERT was approved as a treatment for Fabry disease in the United States in 2003.
Two recombinant enzyme replacement therapies are available to functionally compensate for α-galactosidase deficiency. Agalsidase α and β are both recombinant forms of the human α-galactosidase A enzyme and both have the same amino acid sequence as the native enzyme. Agalsidase α and β differ in the structures of their oligosaccharide side chains.
In Fabry disease patients, 88% percent of patients develop IgG antibodies towards the injected recombinant enzyme, as it is foreign to their immune system. One suggested approach to solving this problem involves converting the paralogous enzyme α-NAGAL (NAGA) into one that has with α-GAL activity. Because patients still have a functional NAGA gene, their immune system will not produce NAGA antibodies.
The pharmaceutical company Shire manufactures agalsidase alfa (INN) under the trade name Replagal as a treatment for Fabry disease, and was granted marketing approval in the EU in 2001. FDA approval was applied for the United States. However, in 2012, Shire withdrew their application for approval in the United States citing that the agency will require additional clinical trials before approval.
The pharmaceutical company Genzyme produces synthetic agalsidase β (INN) under the trade name Fabrazyme for treatment of Fabry disease. In 2009, contamination at Genzyme’s Allston, Massachusetts plant caused a worldwide shortage of Fabrazyme, and supplies were rationed to patients at one-third the recommended dose. Some patients have petitioned to break the company’s patent on the drug under the “march-in” provisions of the Bayh–Dole Act.
Fabry patients who display neurological symptoms cannot receive RERT because recombinant enzymes cannot normally pass the blood-brain barrier. Thus, a more suitable alternative treatment is used: pharmacological chaperone therapy.
It has been shown that more potent competitive inhibitors of an enzyme can act as a more powerful chemical chaperone for the corresponding mutant enzyme that fails to maintain proper folding and conformation, despite its intact active site. These chemical chaperones bind to the active site of the mutant enzyme, which can help promote proper folding and stabilize the mutant enzyme. Thus, this results in functional mutant enzymes that will not be degraded via the ubiquitin-proteasome pathway.
1-Deoxygalactonojirimycin (DGJ) has been shown to be both a potent competitive inhibitor of α-GAL and an effective chaperone to for Fabry disease, increasing intracellular α-GAL’s activity by 14-fold.
α-GAL, known as B-zyme in this context, has also demonstrated its ability to convert human blood group B to human blood group O, which can be transfused to patients of all blood types in the ABO blood group categorization. The current B-zyme used comes from Bacteroides fragilis. The idea of maintaining a blood supply at healthcare facilities with all non-O units converted to O units is achieved using enzyme-converted to group O technology, first developed in 1982.
A blood bank with ECO blood demonstrates the following advantages:
Red blood cell (RBC) surfaces are decorated with the glycoproteins and glycolipids that have the same basic sequence with terminal sugar α1‐2‐linked fucose linked to the penultimate galactose. This galactose molecule is called the H antigen. Blood type A, B, AB, and O differ only in the sugar (red molecule in the illustration) linked with the penultimate galactose. For blood type B, this linked sugar is an α-1‐3‐linked galactose. Using α-GAL, this terminal galactose molecule can be removed, converting RBC to type O.
α-GAL derived from the mold Aspergillus niger is an active ingredient in products marketed to reduce stomach gas production after eating foods known to cause gas. It is optimally active at 55 °C, after which its half-life is 120 minutes.
Commercial products with α-galactosidase include:
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Research has found that anxiety is one of the leading symptoms created by marijuana in users, and that there is a correlation between Agalsidase Beta and Weed and an increase in anxiety.
Anyone mixing Agalsidase Beta and weed is likely to experience side effects. This happens with all medications whether weed or Agalsidase Beta is mixed with them. Side effects can be harmful when mixing Agalsidase Beta and weed. Doctors are likely to refuse a patient a Agalsidase Beta prescription if the individual is a weed smoker or user. Of course, this could be due to the lack of studies and research completed on the mixing of Agalsidase Beta and Weed.
Heavy, long-term weed use is harmful for people. It alters the brain’s functions and structure, and all pharmaceuticals and drugs including Agalsidase Beta are designed to have an impact on the brain. There is a misplaced belief that pharmaceuticals and medication work by treating only the parts of the body affected yet this is obviously not the case in terms of Agalsidase Beta. For example, simple painkiller medication does not heal the injury, it simply interrupts the brains functions to receive the pain cause by the injury. To say then that two drugs, Agalsidase Beta and Weed, dol not interact is wrong. There will always be an interaction between Agalsidase Beta and Weed in the brain11.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/.
One of the milder side effects of mixing Agalsidase Beta and Weed is Scromiting. This condition, reportedly caused by mixing Agalsidase Beta and Weed, describes a marijuana-induced condition where the user experiences episodes of violent vomiting, which are often so severe and painful that they cause the person to scream. The medical term for Scromiting by mixing Agalsidase Beta and Weed is cannabinoid hyperemesis syndrome, or CHS. For these reasons, some people choose to quit smoking weed.
It was first included in scientific reports in 2004. Since then, researchers have determined that Scromiting is the result of ongoing, long-term use of marijuana—particularly when the drug contains high levels of THC, marijuana’s main psychoactive ingredient. Some experts believe that the receptors in the gut become overstimulated by THC, thus causing the repeated cycles of vomiting.
In the long run, a person can become even more depressed. There is a belief that marijuana is all-natural and not harmful to a person’s health. This is not true and Agalsidase Beta and weed can cause health issues the more a person consumes it.
How does Weed effect the potency of Agalsidase Beta?
The way in which the body absorbs and process Agalsidase Beta may be affected by weed. Therefore, the potency of the Agalsidase Beta may be less effective. Marijuana inhibits the metabolization of Agalsidase Beta. Not having the right potency of Agalsidase Beta means a person may either have a delay in the relief of their underlying symptoms.
A person seeking Agalsidase Beta medication that uses weed should speak to their doctor. It is important the doctor knows about a patient’s weed use, so they can prescribe the right Agalsidase Beta medication and strength. Or depending on level of interactions they may opt to prescribe a totally different medication. It is important for the doctor to know about their patient’s marijuana use. Weed is being legalized around the US, so doctors should be open to speaking about a patient’s use of it.
Sideffects of Agalsidase Beta and Weed
Many individuals may not realize that there are side effects and consequences to mixing Agalsidase Beta and Weed such as:
- Dizziness
- Sluggishness
- Drowsiness
- Shortness of breath
- Itching
- Hives
- Palpitations
- Respiratory Depression
- Cardiac Arrest
- Coma
- Seizures
- Death
Interestingly, it is impossible to tell what effect mixing this substance with Weed will have on an individual due to their own unique genetic make up and tolerance. It is never advisable to mix Agalsidase Beta and Weed due to the chances of mild, moderate and severe side effects. If you are having an adverse reaction from mixing Agalsidase Beta and Weed it’s imperative that you head to your local emergency room. Even mixing a small amount of Agalsidase Beta and Weed is not recommended.
Taking Agalsidase Beta and Weed together
People who take Agalsidase Beta and Weed together will experience the effects of both substances. Technically, the specific effects and reactions that occur due to frequent use of Agalsidase Beta and weed depend on whether you consume more weed in relation to Agalsidase Beta or more Agalsidase Beta in relation to weed.
The use of significantly more weed and Agalsidase Beta will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Agalsidase Beta may experience effects such as:
- reduced motor reflexes from Agalsidase Beta and Weed
- dizziness from Weed and Agalsidase Beta
- nausea and vomiting due to Agalsidase Beta and Weed
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Agalsidase Beta leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Mixing weed and Agalsidase Beta
The primary effect of weed is influenced by an increase in the concentration of the inhibitory neurotransmitter GABA, which is found in the spinal cord and brain stem, and by a reduction in its effect on neuronal transmitters. When weed is combined with Agalsidase Beta this primary effect is exaggerated, increasing the strain on the body with unpredictable results.
Weed and Agalsidase Beta affects dopamine levels in the brain, causing the body both mental and physical distress. Larger amounts of Agalsidase Beta and weed have a greater adverse effect yet leading medical recommendation is that smaller does of Agalsidase Beta can be just as harmful and there is no way of knowing exactly how Agalsidase Beta and weed is going to affect an individual before they take it.
Taking Agalsidase Beta and weed together
People who take Agalsidase Beta and weed together will experience the effects of both substances. The use of significantly more Agalsidase Beta with weed will lead to sedation and lethargy, as well as the synergistic effects resulting from a mixture of the two medications.
People who take both weed and Agalsidase Beta may experience effects such as:
- reduced motor reflexes from Agalsidase Beta and weed
- dizziness from weed and Agalsidase Beta
- nausea and vomiting of the Agalsidase Beta
Some people may also experience more euphoria, depression, irritability or all three. A combination of weed and Agalsidase Beta leads to significantly more lethargy which can easily tip over into coma, respiratory depression seizures and death.
Weed Vs Agalsidase Beta
Taking Agalsidase Beta in sufficient quantities increases the risk of a heart failure. Additionally, people under the influence of Agalsidase Beta and weed may have difficulty forming new memories. With weed vs Agalsidase Beta in an individual’s system they become confused and do not understand their environment. Due to the synergistic properties of Agalsidase Beta when mixed with weed it can lead to confusion, anxiety, depression and other mental disorders. Chronic use of Agalsidase Beta and weed can lead to permanent changes in the brain22.G. Lafaye, L. Karila, L. Blecha and A. Benyamina, Cannabis, cannabinoids, and health – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741114/.
Agalsidase Beta Vs Weed
Studies investigating the effects of drugs such as Agalsidase Beta and weed have shown that the potential for parasomnia (performing tasks in sleep) is dramatically increased when Agalsidase Beta and weed are combined. Severe and dangerous side effects can occur when medications are mixed in the system, and sleep disorders are a common side effect of taking weed and Agalsidase Beta together.
When a small to medium amount of weed is combined with Agalsidase Beta, sleep disorders such as sleep apnea can occur. According to the latest data from the US Centers for Disease Control and Prevention (CDC) most ER visits and hospitalizations caused by too much weed were associated with other substances such as Agalsidase Beta.
How long after taking Agalsidase Beta can I smoke weed or take edibles?
To avoid any residual toxicity it is advisable to wait until the Agalsidase Beta has totally cleared your system before taking weed, even in small quantities.
Overdose on Agalsidase Beta and weed
In the case of Overdose on Agalsidase Beta or if you are worried after mixing Agalsidase Beta and weed, call a first responder or proceed to the nearest Emergency Room immediately.
If you are worried about someone who has taken too much Agalsidase Beta or mixed weed with Agalsidase Beta then call a first responder or take them to get immediate medical help. The best place for you or someone you care about in the case of a medical emergency is under medical supervision. Be sure to tell the medical team that there is a mix of Agalsidase Beta and weed in their system.
Excessive Weed intake and result in scromiting, chs, and anxiety disorder. It is advisable to quit vaping weed if you are feeling these symptoms.
Mixing Agalsidase Beta and weed and antidepressants
Weed users feeling depressed and anxious may be prescribed antidepressant medication. There are some antidepressant users who also use Agalsidase Beta and weed. These individuals may not realize that there are side effects and consequences to consuming both Agalsidase Beta, marijuana and a range of antidepressants.
Studies on weed, Agalsidase Beta and antidepressants is almost nil. The reason for so little information on the side effects of the two is mostly down to marijuana being illegal in most places – although a number of states in the United States have legalized the drug.
Self-medicating with Weed and Agalsidase Beta
A lot of people suffer from depression caused by weed and Agalsidase Beta. How many? According to Anxiety and Depression Association of America (ADAA), in any given year, it is estimated that nearly 16 million adults experience depression. Unfortunately, that number is likely to be wrong due to under reporting. Many people do not report suffering from depression because they do not want to be looked at as suffering from a mental illness. The stigmas around mental health continue and people do not want to be labeled as depressed.
Potential side effects from mixing Agalsidase Beta and weed
Quitting weed to take Agalsidase Beta
Medical professionals say an individual prescribed or taking Agalsidase Beta should not stop using weed cold turkey. Withdrawal symptoms can be significant. Heavy pot users should especially avoid going cold turkey. The side effects of withdrawal from weed include anxiety, irritability, loss of sleep, change of appetite, and depression by quitting weed cold turkey and starting to take Agalsidase Beta.
A person beginning to use Agalsidase Beta should cut back on weed slowly. While reducing the amount of weed use, combine it with mindfulness techniques and/or yoga. Experts stress that non-medication can greatly improve a person’s mood.
Weed and Agalsidase Beta can affect a person in various ways. Different types of marijuana produce different side effects. Side effects of weed and Agalsidase Beta may include:
- loss of motor skills
- poor or lack of coordination
- lowered blood pressure
- short-term memory loss
- increased heart rate
- increased blood pressure
- anxiety
- paranoia
- increased energy
- increased motivation
Mixing Agalsidase Beta and weed can also produce hallucinations in users. This makes marijuana a hallucinogenic for some users. Weed creates different side effects in different people, making it a very potent drug. Now, mixing Agalsidase Beta or other mental health drugs with weed can cause even more unwanted side effects.
Mixing drugs and weed conclusion
Long-term weed use can make depression and anxiety worse. In addition, using marijuana can prevent Agalsidase Beta from working to their full potential33.J. D. Brown and A. G. Winterstein, Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use – PMC, PubMed Central (PMC).; Retrieved September 27, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678684/. Weed consumption should be reduced gradually to get the most out of prescription medication. Marijuana is a drug and it is harmful to individual’s long-term health. Weed has many side effects and the consequences are different to each person who uses it, especially when mixed with Agalsidase Beta.
If you take Agalsidase Beta, and also drink Alcohol or MDMA, you can research the effects of Agalsidase Beta and Alcohol , Agalsidase Beta and Cocaine as well as Agalsidase Beta and MDMA here.
To find the effects of other drugs and weed refer to our Weed and Other Drugs Index A to L or our Weed and Other Drugs Index M-Z.
Or you could find what you are looking for in our Alcohol and Interactions with Other Drugs index A to L or Alcohol and Interactions with Other Drugs index M to Z , Cocaine and Interactions with Other Drugs index A to L or Cocaine and Interactions with Other Drugs index M to Z or our MDMA and Interactions with Other Drugs Index A to L or MDMA and Interactions with Other Drugs Index M to Z.
Agalsidase Beta and Weed
Counselling for Weed Addiction; Low Cost - Qualified Therapists - Available Now - 20% Off
We may make a commission if you purchase anything via the adverts or links on this page.
Betterhelp is for anyone suffering from mental health issues. Whether you suffer from anxiety, depression, weed addiction, eating disorders, or just need someone to speak to, Betterhelp can pair you with a qualified therapist.
In the wake of the pandemic, an increasing number of people have sought out therapeutic and conseling services to help with weed cessation. Better Help has seen a massive rise in people seeking help over the last two to three years.
If you or someone you care about is smoking or ingesting a level of weed that makes their life become unmanageable, Betterhelp has counselors and therapists on hand to help for less that $90 per week.
Specializations | Burnout, Anxiety, Depression, Stress, Anger Management, Dependencies, Grief, Seasonal Depressive Disorder, Life Crisis, Smoking Cessation, Weed Cessation (among others)
Betterhelp Cost | The standard fee for BetterHelp therapy is only $60 to $90 per week or $240 to $360 per month.
Key Takeaways |
- Largest online therapy platform
- Low cost
- Good for stopping weed
- Messaging
- Live video
- Phone calls
- Live chat
- No lock in contracts
- Cancel anytime
- Licensed and accredited therapists
Discounts Available | We have negotiated a generous 20% discount for readers of our website. Press Here to get 20% Off
